DoD Tuberous Sclerosis Complex Clinical Translational Research Award | W81XWH 18 TSCRP CTRA

Opportunity Information: Apply for W81XWH 18 TSCRP CTRA

The DoD Tuberous Sclerosis Complex Clinical Translational Research Award (funding opportunity number W81XWH 18 TSCRP CTRA) is a Department of Defense research funding opportunity administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is intended to accelerate meaningful progress in tuberous sclerosis complex (TSC) by supporting clinical and translational research that deliberately connects laboratory discovery and patient-focused investigation. The central idea is a two-way, iterative exchange between basic science and clinical science, where findings in one setting directly shape questions, methods, and next steps in the other, with the end goal of improving how TSC is diagnosed, how outcomes are predicted (prognosis), and how the condition is treated.

This program specifically encourages projects that move in either direction along the translational pipeline. On the "forward" side, it can support studies that take promising preclinical results and advance them toward clinical research, including a pilot clinical trial when appropriate. On the "reverse" side, it can support efforts that start from human clinical observations and data, such as analyzing patient specimens (human anatomical substances) and datasets generated in the context of clinical trials, including correlative studies. These human-derived insights are then used to build or refine experimental models that better mirror real clinical outcomes, helping researchers test hypotheses and interventions in ways that are more likely to translate back to patient benefit.

From an administrative and eligibility standpoint, the opportunity falls under the Science and Technology and other Research and Development category and is listed under CFDA number 12.420. The funding can be provided as either a cooperative agreement or a grant, meaning applicants may need to be prepared for varying levels of government involvement depending on the award structure used. Eligibility is listed as unrestricted, which generally means applications may be submitted by a broad range of organization types, assuming no additional limitations are specified elsewhere in the full announcement. The opportunity was originally posted on May 14, 2018, with an original closing date of August 2, 2018, and it anticipated making two awards. The listing shows an award ceiling of 0, which typically indicates that a specific maximum amount was not provided in the summary field and would need to be confirmed in the full solicitation details.

Overall, the award is geared toward well-justified translational projects that can demonstrate a clear feedback loop between clinical realities in TSC and mechanistic or model-based research, while keeping a strong line of sight to practical improvements in patient care.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Tuberous Sclerosis Complex Clinical Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 14, 2018.
• Applicants must submit their applications by Aug 02, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 18 TSCRP CTRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: